Oxford Biomedica (otc)
Oxford BioMedica (OXB) is a leading gene and cell therapy company based in the UK, specializing in the development of innovative treatments for serious diseases. The company focuses on developing advanced therapeutic modalities utilizing its proprietary LentiVector® platform, which enables the delivery of genes to target cells effectively. OXB operates primarily in the biotechnology sector, collaborating with pharmaceutical companies and academic institutions to bring new therapies to market, particularly in areas such as oncology, ophthalmology, and neurodegenerative diseases.